We are developing antibody–drug conjugates (ADCs) using molecular glue degraders as the payload. Molecular glues readily conjugate with linkers and demonstrate efficacy at low drug concentrations. By applying this approach to ADCs, we aim to create a new class of ADCs with enhanced efficacy and safety.